Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours

13

Autores:
Trojan, Jerzy
Pan, Yuexin X.
Wei, Ming X.
Ly, Adama
Shevelev, Alexander
Bierwagen, Maciej
Ardourel, Marie Yvonne
Trojan, Ladislas A.
Alvarez, Alvaro
Andres, Christian
Noguera, Maria C.
Briceño Balcázar, Ignacio
Aristizabal, Beatriz H.
Kasprzak, Heliodor
Duc, Huynh T.
Anthony, Donald D.
Tipo de recurso:
Fecha de publicación:
2012
Institución:
Universidad de la Sabana
Repositorio:
Repositorio Universidad de la Sabana
Idioma:
eng
OAI Identifier:
oai:intellectum.unisabana.edu.co:10818/37537
Acceso en línea:
https://www.hindawi.com/journals/cherp/2012/721873/
http://downloads.hindawi.com/archive/2012/721873.pdf
http://hdl.handle.net/10818/37537
Palabra clave:
Rights
License
Attribution-NonCommercial-NoDerivatives 4.0 International
id REPOUSABA2_792a6e451b239f3f139b5a62a3335cad
oai_identifier_str oai:intellectum.unisabana.edu.co:10818/37537
network_acronym_str REPOUSABA2
network_name_str Repositorio Universidad de la Sabana
repository_id_str
spelling Trojan, JerzyPan, Yuexin X.Wei, Ming X.Ly, AdamaShevelev, AlexanderBierwagen, MaciejArdourel, Marie YvonneTrojan, Ladislas A.Alvarez, AlvaroAndres, ChristianNoguera, Maria C.Briceño Balcázar, IgnacioAristizabal, Beatriz H.Kasprzak, HeliodorDuc, Huynh T.Anthony, Donald D.10/7/2019 10:222019-10-07T15:22:21Z2012https://www.hindawi.com/journals/cherp/2012/721873/http://downloads.hindawi.com/archive/2012/721873.pdfhttp://hdl.handle.net/10818/3753710.1155/2012/72187313The aim of this study was to establish the criteria for methodology of cellular “anti-IGF-I” therapy of malignant tumours and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix expression vectors. The prepared cell “vaccines” should it be in the case of glioblastomas or other tumours, have shown a change of phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. The peripheral blood lymphocytes, PBL cells, removed after each of two successive vaccinations, have demonstrated for all the types of tumour tested an increasing level of CD8+ and CD8+28+ molecules and a switch from CD8+11b+ to CD8+11. All cancer patients were supervised for up to 19 months, the period corresponding to minimum survival of glioblastoma patients. The obtained results have permitted to specify the common criteria for “anti-IGF-I” strategy: characteristics sine qua non of injected “vaccines” (cloned cells IGF-I(−) and MHC-I(+)) and of PBL cells (CD8+ increased level)application/pdfengChemotherapy Research and PracticeChemotherapy Research and Practice Volume 2012, Article ID 721873Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_abf2Universidad de La SabanaIntellectum Repositorio Universidad de La SabanaMethodology for Anti-Gene Anti-IGF-I Therapy of Malignant TumoursMethodology for Anti Gene Anti IGI I Therapy of Malignant TumoursarticlepublishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://intellectum.unisabana.edu.co/bitstream/10818/37537/2/license_rdf4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8498https://intellectum.unisabana.edu.co/bitstream/10818/37537/3/license.txtf52a2cfd4df262e08e9b300d62c85cabMD5310818/37537oai:intellectum.unisabana.edu.co:10818/375372022-05-10 05:19:43.66Intellectum Universidad de la Sabanacontactointellectum@unisabana.edu.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
dc.title.es_CO.fl_str_mv Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
dc.title.alternative.en.fl_str_mv Methodology for Anti Gene Anti IGI I Therapy of Malignant Tumours
title Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
spellingShingle Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
title_short Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
title_full Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
title_fullStr Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
title_full_unstemmed Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
title_sort Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours
dc.creator.fl_str_mv Trojan, Jerzy
Pan, Yuexin X.
Wei, Ming X.
Ly, Adama
Shevelev, Alexander
Bierwagen, Maciej
Ardourel, Marie Yvonne
Trojan, Ladislas A.
Alvarez, Alvaro
Andres, Christian
Noguera, Maria C.
Briceño Balcázar, Ignacio
Aristizabal, Beatriz H.
Kasprzak, Heliodor
Duc, Huynh T.
Anthony, Donald D.
dc.contributor.author.none.fl_str_mv Trojan, Jerzy
Pan, Yuexin X.
Wei, Ming X.
Ly, Adama
Shevelev, Alexander
Bierwagen, Maciej
Ardourel, Marie Yvonne
Trojan, Ladislas A.
Alvarez, Alvaro
Andres, Christian
Noguera, Maria C.
Briceño Balcázar, Ignacio
Aristizabal, Beatriz H.
Kasprzak, Heliodor
Duc, Huynh T.
Anthony, Donald D.
description 13
publishDate 2012
dc.date.accessioned.none.fl_str_mv 10/7/2019 10:22
dc.date.issued.none.fl_str_mv 2012
dc.date.available.none.fl_str_mv 2019-10-07T15:22:21Z
dc.type.en.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.hasVersion.es_CO.fl_str_mv publishedVersion
dc.identifier.other.none.fl_str_mv https://www.hindawi.com/journals/cherp/2012/721873/
http://downloads.hindawi.com/archive/2012/721873.pdf
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/10818/37537
dc.identifier.doi.none.fl_str_mv 10.1155/2012/721873
url https://www.hindawi.com/journals/cherp/2012/721873/
http://downloads.hindawi.com/archive/2012/721873.pdf
http://hdl.handle.net/10818/37537
identifier_str_mv 10.1155/2012/721873
dc.language.iso.es_CO.fl_str_mv eng
language eng
dc.relation.ispartofseries.none.fl_str_mv Chemotherapy Research and Practice Volume 2012, Article ID 721873
dc.rights.*.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
dc.format.es_CO.fl_str_mv application/pdf
dc.publisher.es_CO.fl_str_mv Chemotherapy Research and Practice
dc.source.es_CO.fl_str_mv Universidad de La Sabana
Intellectum Repositorio Universidad de La Sabana
institution Universidad de la Sabana
bitstream.url.fl_str_mv https://intellectum.unisabana.edu.co/bitstream/10818/37537/2/license_rdf
https://intellectum.unisabana.edu.co/bitstream/10818/37537/3/license.txt
bitstream.checksum.fl_str_mv 4460e5956bc1d1639be9ae6146a50347
f52a2cfd4df262e08e9b300d62c85cab
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Intellectum Universidad de la Sabana
repository.mail.fl_str_mv contactointellectum@unisabana.edu.co
_version_ 1811952201932734464

Publicaciones similares